Develops off-the-shelf hematopoietic stem cell therapies that generate self-renewing, HLA-compatible, and transgene-free blood stem cells from depleted patient or donor cells. This approach eliminates the need for matched donors, providing a scalable solution to treat over 120 severe diseases, including hematological and oncological conditions.
Funding
$181.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients requiring hematopoietic stem cell transplants often face challenges in finding suitable HLA-matched donors, leading to delays and potential complications. The reliance on donor or patient-derived cells limits the accessibility and scalability of stem cell therapies for severe blood and immune disorders. Traditional transplant approaches carry the risk of graft-versus-host disease and may not provide durable, long-term engraftment.
Solution
Stratus Therapeutics is developing off-the-shelf hematopoietic stem cell (HSC) therapies designed to eliminate the need for matched donors and provide rapid access to consistent, durable stem cell treatments. The Stratus Prime™ platform delivers Prime HSCs™ and Prime HPCs™ to restore blood and immune systems, offering a universal graft solution for a range of severe blood and immune disorders. Their lead product, ST-101, contains both Prime HSCs™ and Prime HPCs™, enabling near-term immune recovery and durable, long-term engraftment, while minimizing the risk of graft-versus-host disease. Stratus's approach leverages induced pluripotent stem cell (iPSC) technology and chemical replication of the aorta-gonad-mesonephros (AGM) region to generate HSCs and hematopoietic progenitor cells (HPCs) in the laboratory. The initial clinical focus includes patients with acquired or inherited bone marrow failure syndromes (BMFS) and transfusion-dependent beta thalassemia (TDT), with the goal of expanding into all indications where hematopoietic stem cell transplantation is currently used.
Target Audience
The primary target audience includes patients with severe blood and immune disorders, such as acquired or inherited bone marrow failure syndromes and transfusion-dependent beta thalassemia, as well as physicians seeking accessible and effective stem cell transplant solutions.
Features
- Off-the-shelf hematopoietic stem cell (HSC) therapies, eliminating the need for HLA-matched donors
- Stratus Prime™ platform delivering Prime HSCs™ and Prime HPCs™ for blood and immune system restoration
- ST-101, a lead product containing both Prime HSCs™ and Prime HPCs™ for near-term immune recovery and durable engraftment
- Minimized risk of graft-versus-host disease through effective T-cell depletion in manufactured grafts
- Utilizes induced pluripotent stem cell (iPSC) technology to generate HSCs and HPCs
- Chemical replication of the aorta-gonad-mesonephros (AGM) region for HSC production
- Master cell bank with the potential to HLA-match a significant percentage of the US and European populations